Sangamo BioSciences | SGMO - Net Income


Sangamo BioSciences reported $-36.13M in Net Income for its fiscal quarter ending in June of 2024.





Net Income Change Date
Alaunos Therapeutics USD -1.16M 108K Sep/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Alterity Therapeutics Limited AUD -5.77M 2.26M Jun/2023
Amgen USD 1.33B 1.88B Dec/2025
Bayer EUR -3.76B 2.79B Dec/2025
BioCryst Pharmaceuticals USD 245.84M 232.95M Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
BioMarin Pharmaceutical USD -46.57M 15.83M Dec/2025
Cipla INR 6.76B 6.75B Dec/2025
Clal Biotechnology ILS -6.17M 15.56M Dec/2022
Compugen USD 56.84M 63.82M Dec/2025
CSL USD 401M 96.5M Dec/2025
Gilead Sciences USD 2.18B 869M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
Grifols EUR 114.37M 34.03M Dec/2025
Ionis Pharmaceuticals USD -229M 100.39M Dec/2025
J&J USD 5.12B 36M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Omeros USD -32.23M 23.81M Sep/2024
Pfizer USD -1.65B 5.19B Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Sangamo BioSciences USD -36.13M 12.96M Jun/2024
Sanofi EUR -801M 3.6B Dec/2025
Sarepta Therapeutics USD -412.23M 232.28M Dec/2025
Tectonic Therapeutic USD -19.23M 186K Dec/2025
Ultragenyx Pharmaceutical USD -129M 51.41M Dec/2025
Vertex Pharmaceuticals USD 1.19B 108.2M Dec/2025